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Abstract: In the United States, federally-funded health plans are mandated to measure the quality
of care. Adherence-based medication quality metrics depend on completeness of administrative
claims data for accurate measurement. Low-cost generic programs (LCGPs) cause medications fills
to be missing from claims data as medications are not adjudicated through a patient’s insurance.
This study sought to assess the magnitude of the impact of LCGPs on these quality measures.
Data from the 2012–2013 Medical Expenditure Panel Survey (MEPS) were used. Medication fills
for select medication classes were classified as LCGP fills and individuals were classified as never,
sometimes, and always users of LCGPs. Individuals were classified based on insurance type (private,
Medicare, Medicaid, dual-eligible). The proportion of days covered (PDC) was calculated for each
medication class and the proportion of users with PDC ≥ 0.80 was reported as an observed metric for
what would be calculated based on claims data and a true metric which included missing medication
fills due to LCGPs. True measures of adherence were higher than the observed measures. The effect’s
magnitude was highest for private insurance and for medication classes utilized more often through
LCGPs. Thus, medication-based quality measures may be underestimated due to LCGPs.
Keywords: low-cost generic medications; quality measurement; adherence
1. Introduction
Low-cost generic drug programs (LCGPs) in the United States (U.S.) increase the affordability
and accessibility of prescription medication [1]. LCGPs are unique to the U.S market as a “loss-leader”
pricing strategy, i.e., retailers accept a loss on these cheap medications to bring in customers. LCGPs are
available at 8 of the top 10 pharmacy chains (e.g., Wal-Mart, Walgreens) and provide many of the
most commonly used generic medications at copayments of $4–$5 for 30-day supplies or $10–$12
for 90-day supplies [1–3]. These prices are generally lower than the insurance co-payment for the
medications; thus, patients using these programs acquire the medications without the insurance
company’s knowledge.
Our group recently assessed the prevalence and patient characteristics associated with LCGP
use among those who are privately [4] and publicly (Medicare) [5] insured as well as in uninsured [6]
and pediatric [7] populations. In each study, we analyzed which medications are most commonly
purchased through LCGPs, the prevalence of LCGP use at the individual level, and the predictors of
LCGP use in nationally representative samples. These studies indicate that there is a higher prevalence
of LCGP use than has been estimated in previous literature. Using these programs, a claim may not be
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submitted through an individual’s insurance benefit; thus, medication use data can be missing from
administrative claims data. In the U.S., administrative claims are widely used as a data source for
health plans to assess quality of care, safety surveillance, and research [8,9].
Quality measurement is mandated by the federal government for publicly funded insurance
programs including Medicaid and Medicare Advantage (Part C) and Part D plans. The measures are
based on a standard set of measures—including several regarding pharmaceutical utilization [10,11].
Medications filled through LCGPs may go unobserved in claims data, leading to an underestimation
of overall medication use and potentially a lower quality score. These scores are particularly important
considering that they have been linked to plan enrollment and can impact quality-based reimbursement
packages in a “pay-for-performance” healthcare environment [12,13].
This study sought to empirically assess the impact LCGPs may have on quality measurement for
health insurance plans by identifying individuals and medications fills which may be unobserved due
to LCGP use. For the purpose of this analysis, we calculated the quality metric for the proportion of
days covered (PDC) of several drug classes that are assessed by quality measures and are available
through LCGPs [14].
2. Materials and Methods
2.1. Data Source
This study used data from the Medical Expenditure Panel Survey (MEPS) from the years
2012–2013. These years were chosen as they are the two most recent years for which MEPS data
are available. MEPS is a nationally representative survey of individuals living in the United States that
collects data regarding demographics and clinical conditions, as well as healthcare and pharmaceutical
utilization. MEPS is a de-identified public use dataset supported by the Agency for Healthcare Research
and Quality (AHRQ) that is intended for research purposes; therefore, it is exempt from IRB approval.
Details related to the design and data collection processes of MEPS are detailed elsewhere [15].
2.2. Study Design and Population
A retrospective longitudinal study design was used to compare medication adherence that would
be observed by health plans to that which may go unobserved due to use of LCGPs. Individuals were
included in the study sample if they completed all five rounds of MEPS data collection, participated in
the pharmacy survey, and reported having any public (Medicare, Medicaid, dual) or private insurance
coverage. Subjects who were uninsured were excluded. Study subjects were required to have at
least two fills of a medication in non-consecutive rounds for one of the following medication classes:
angiotensin converting enzyme inhibitors (ACEi), beta-blockers, calcium channel blockers, HMG Co-A
reductase inhibitors (statins), metformin, and sulfonylureas. These inclusion criteria were selected to
be as similar as possible to the criteria used to calculate PDC for standard HEDIS measures [11,14].
2.3. LCGP Use
Four stipulations were used to define LCGP use [4–7]: (1) The total cost of the drug was paid out
of pocket; (2) The cost of the drug exactly matched the cost of an LCGP drug as reported by pharmacies;
(3) The medication was listed as an LCGP from a major chain pharmacy; and (4) Medications were
dispensed for 30 or 90 days supplied of medications. Individuals were classified as always, sometimes,
or never using LCGPs to fill medications for each medication class.
2.4. Outcome Measures
PDC was calculated for each person during calendar years 2012 and 2013 for each medication
class of interest by summing the total number of days supplied of medication, divided by 365 days.
In cases where the days supplied variable was missing, the value was imputed based off mean days
supply given the quantity of drug dispensed by National Drug Code [16].
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Two distinct PDC measures were derived to demonstrate the effect of LCGP medications on
quality measurement. The observed PDC only considers individuals and fills that would be observed
in administrative claims data including all non-LCGP fills by individuals who sometimes or never used
LCGPs. LCGP fills were excluded as these fills would not be observed in claims, thus having a potential
detrimental impact on calculation of PDC as medication users are included in the denominator,
but missing fills are absent from the calculation. The true PDC measure represents the PDC that
a health plan would have derived had it observed LCGP fills for individuals who sometimes used
LCGPs. PDC was not calculated for “always” users as they would never be observed in claims data.
However, the implications of these LCGP users was discussed.
The frequency distribution of individuals classified as always, sometimes, and never LCGP users
was calculated for each insurance type and was stratified by medication class. Mean PDC as well as
the proportion of individuals with a PDC greater than or equal to 0.8 was calculated for each PDC
measure and was stratified by medication class and insurance type. All data analyses were conducted
using SAS 9.4 (SAS Institute, Cary, NC, USA).
3. Results
Table 1 shows the number of users for each medication class and the distribution by insurance type.
A higher proportion of private insurance beneficiaries were classified as always or sometimes using
LCGPs compared to those with public insurance. The greatest proportions of individuals classified as
never using LCGPs were observed for the dual-eligible and Medicare populations. This difference
is likely driven by higher deductibles and copayment amounts paid for prescription medications,
with public insurance types typically paying much less and less incentive to use LCGPs due to cost.
Table 1. Users of low-cost generic programs (LCGPs) by insurance status for each medication class.
Insurance Never Use LCGPs Always Use LCGPs Sometimes Use LCGPs
ACE inhibitors
(N = 1861)
Private N (%) 386 (58.8) 119 (18.1) 152 (23.1)
Medicaid N (%) 164 (84.5) 8 (4.1) 22 (11.3)
Medicare N (%) 599 (74.3) 69 (8.6) 138 (17.1)
Dual N (%) 181 (88.7) 9 (4.4) 14 (6.9)
Beta-blockers
(N = 1847)
Private N (%) 341 (65.8) 78 (15.1) 99 (19.1)
Medicaid N (%) 115 (81.0) 8 (5.6) 19 (13.4)
Medicare N (%) 753 (78.8) 63 (6.6) 140 (14.6)
Dual N (%) 215 (93.1) 3 (1.3) 13 (5.6)
Calcium channel blockers
(N = 1207)
Private N (%) 239 (72.4) 35 (10.6) 56 (17.0)
Medicaid N (%) 80 (92.0) 1 (1.2) 6 (6.9)
Medicare N (%) 515 (86.6) 21 (3.5) 59 (9.9)
Dual N (%) 190 (97.4) 0 (0) 5 (2.6)
Statins
(N = 2714)
Private N (%) 669 (76.1) 65 (7.4) 145 (16.5)
Medicaid N (%) 177 (92.2) 2 (1.0) 13 (6.8)
Medicare N (%) 1139 (88.3) 34 (2.6) 117 (9.1)
Dual N (%) 342 (96.9) 2 (0.6) 9 (2.6)
Metformin
(N = 1030)
Private N (%) 213 (59.8) 61 (17.1) 82 (23.0)
Medicaid N (%) 107 (83.6) 3 (2.3) 18 (14.1)
Medicare N (%) 288 (72.9) 52 (13.2) 55 (13.9)
Dual N (%) 142 (94.0) 2 (1.3) 7 (4.6)
Sulfonylureas
(N = 473)
Private N (%) 81 (63.8) 15 (11.8) 31 (24.4)
Medicaid N (%) 51 (85.0) 2 (3.3) 7 (11.7)
Medicare N (%) 152 (71.7) 22 (10.4) 38 (17.9)
Dual N (%) 70 (94.6) 1 (1.4) 3 (4.1)
Table 2 shows the results of the PDC calculations for each medication and insurance category
including the overall and true measures of adherence. The mean PDC across measurements was
marginally different for each comparison. For example, the observed PDC was 0.80 for ACEi users
with private insurance and increased to 0.82 accounting for LCGP fills.
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Table 2. Proportion of days covered (PDC) for each medication class by insurance type based on
low-cost generic program utilization.
Medication Class Insurance Observed a True b
ACE inhibitors
Mean (SD)
% PDC ≥ 0.80
Private 0.80 (0.24)54.3%
0.82 (0.22)
64.2%
Medicaid 0.80 (0.23)61.9%
0.82 (0.22)
65.5%
Medicare 0.84 (0.22)67.9%
0.85 (0.21)
70.1%
Dual 0.87 (0.18)76.9%
0.87 (0.18)
77.9
Beta-blockers
Mean (SD)
% PDC ≥ 0.80
Private 0.82 (0.23)64.0%
0.83 (0.22)
66.8%
Medicaid 0.81 (0.24)66.4%
0.83 (0.23)
69.3%
Medicare 0.85 (0.22)70.7%
0.86 (0.21)
72.1%
Dual 0.89 (0.17)82.2%
0.90 (0.17)
82.6%
Calcium channel blockers
Mean (SD)
% PDC ≥ 0.80
Private 0.76 (0.26)57.5%
0.79 (0.25)
61.3%
Medicaid 0.79 (0.24)61.7%
0.80 (0.24)
62.8%
Medicare 0.84 (0.22)69.7%
0.85 (0.22)
71.0%
Dual 0.82 (0.23)71.9%
0.83 (0.23)
72.3%
Statins
Mean (SD)
% PDC ≥ 0.80
Private 0.82 (0.23)63.3%
0.83 (0.22)
66.1%
Medicaid 0.82 (0.22)66.7%
0.83 (0.21)
68.6%
Medicare 0.85 (0.21)70.0%
0.85 (0.21)
71.2%
Dual 0.84 (0.21)69.6%
0.85 (0.21)
70.3%
Metformin
Mean (SD)
% PDC ≥ 0.80
Private 0.79 (0.24)57.9%
0.81 (0.23)
61.5%
Medicaid 0.83 (0.22)68.7%
0.83 (0.21)
70.9%
Medicare 0.86 (0.21)71.4%
0.86 (0.20)
73.4%
Dual 0.88 (0.18)76.4%
0.88 (0.18)
78.2%
Sulfonylureas
Mean (SD)
% PDC ≥ 0.80
Private 0.83 (0.23)66.3%
0.83 (0.23)
68.4%
Medicaid 0.79 (0.24)61.3%
0.80 (0.24)
61.3%
Medicare 0.83 (0.23)67.0%
0.84 (0.22)
68.6%
Dual 0.85 (0.21)72.6%
0.86 (0.20)
73.8%
a Observed: Includes all non-LCGP fills for individuals who never and sometimes use LCGPs. Includes individuals
who never and sometimes use LCGPs for calculation of % PDC ≥ 0.80; b True: Includes all fills for individuals who
never and sometimes use LCGPs. Denominator of patients is same as Observed.
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The impact of LCGPs on quality measures is shown by the proportion of people classified as
having PDC ≥ 0.80 as this is the measure of interest for adherence-based quality measures. In the ACEi
private insurance group, accounting for LCGP fills for those who sometimes use LCGPs, increased the
proportion of individuals with PDC ≥ 0.80 by nearly 10%. The magnitude of this effect varied by
insurance types and by medication class, driven by the proportion of fills attained for each medication
through LCGPs.
4. Discussion
The potential impact of LCGPs on quality measurement for health insurers has been
acknowledged for some time [1]. However, this is the first known study to empirically demonstrate
how quality measurement may be impacted by these programs. Prior studies have shown potential
cost-savings to health plans if members use LCGPs, effectively offloading the burden of medication
costs from the insurer to the pharmacy chain [17,18]. Despite the potential for cost-savings,
these programs undermine quality measurement efforts by health plans and, ultimately, may impact
the net revenue of these companies as payment and enrollment are increasingly being tied to a plan’s
quality measures [12,13]. If health plans can ensure that all medication fills are recorded while their
members continue to use these cash-payment systems, the potential for cost savings to both the patient
and health plan may be substantial [17].
Adherence-focused quality metrics are based off of benchmarks for all health plans. For example,
Medicare Advantage and Medicare Part D plans are assigned a 1-to-5 star ranking based on the
proportion of members attaining a PDC ≥ 0.80 [19]. The cut points between star ratings are often
differences of only a few percentage points, making even a small change in the proportion of members
who are adherent potentially relevant to a plan’s rating [19]. Calculation of measures that define these
star ratings is an imperfect process, and several of these shortcomings are present in this study design
as well. Plans may under-calculate adherence for individuals who are taken off of medications or
switched to medications in other classes. The present study design also under-calculated adherence
for these individuals. Fortunately, since star ratings are relative measures, and every plan will likely
under-calculate these metrics for a similar proportion of the population, this does not immediately
impact the findings of this study nor the cut points for star ratings themselves. However, plans that
can account for medication fills through cash payment systems like LCGPs could gain a competitive
advantage and attain higher quality measures.
Quality measures considering beneficial medications will be underestimated due to LCGP use;
resulting in lower plan ratings for these measures and incorrectly suggesting that a plan’s membership
is receiving lower quality of care. It is in a health plan’s best interest to be able to accurately estimate
the true metric in these cases and implement interventions which capture the utilization of these
medications. Managed care organizations providing Part D and Medicare Advantage plans have
acknowledged the issue of LCGPs as it pertains to quality measurement and should continue to
look for ways to work directly with pharmacies to ensure reporting of LCGP medication fills [10].
Commercial solutions have been developed [20], but more research is needed to determine the impact
of such interventions on both the patient’s out-of-pocket expenditures and the health plan’s total costs
and quality measurement.
Although individuals who always filled medications through LCGPs were included in this study,
these beneficiaries will not directly impact adherence rates calculated by health plans. Adherence-based
quality metrics are only derived for individuals who fill multiple prescriptions for certain drugs in
a given year. If all of an individual’s medication fills are through LCGPs then a health plan may never
classify this person as a medication user and they will not contribute to the overall mean adherence
of a health plan’s population. In this study, individuals who always used LCGPs had comparable
adherence rates to those who sometimes or never used LCGPs. The failure to observe their medication
use will not directly hurt the adherence calculation. However, failing to observe use of certain
medications may harm other quality metrics calculated by health plans. For example, some quality
Pharmacy 2017, 5, 15 6 of 7
metrics stipulate that certain drugs be prescribed after some adverse medical events—i.e., beta blockers
post myocardial infarction (MI). If a beneficiary exclusively fills beta blockers through LCGPs this
subsequent medication use will be unobserved and thus make health plans appear worse off.
There are several ways to mitigate the potential for unobserved medication use due to LCGPs.
If pharmacists file claims even when patients pay entirely out-of-pocket, then LCGP utilizations will
appear in administrative claims data as zero paid claims. The problem with this solution is that
pharmacists and patients do not currently have any incentive to file claims for customers paying
out-of-pocket [1]. Pharmacists may be unaware of a patient’s insurance status or may find obtaining
this information unnecessary especially if they believe that submitting a claim will result in a copay that
exceeds the LCGP fee. While anecdotally this is a common occurrence, Medicare plans can consider
the cost of an LCGP-purchased medication as the “usual and customary” prices, which can then be
reimbursed at the typical level of the given plan (e.g., copay of $1 for a $4 30-day supply)—making
it an even more affordable option [21]. A system-wide change (e.g., via mandate from the Centers
for Medicare and Medicaid Services) is likely needed to dissuade missing information in claims
data. However, policy makers need to be aware of the factors that drive the use of LCGPS—mainly
accessibility and affordability of prescription drugs, and take this into account so that patients do not
experience interruptions in care.
5. Conclusions
LCGPs offer an affordable means to receive affordable generic medications and are being widely
used in the U.S. Given the potential impact of LCGP use on quality measurement in health care
systems, insurers should look for solutions that increase the reporting of LCGP medication use without
interrupting the affordable access to medications which drives the demand of these programs.
Author Contributions: Joshua D. Brown conceived and designed the study. Nathan J. Pauly performed the data
analysis. All authors interpreted the data and drafted the manuscript.
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